MRNA
Moderna, Inc.
NASDAQ · Healthcare · Biotechnology · US
$241.46
−6.55%Price chart
Oct 7Oct 12Oct 15Oct 20Oct 23Oct 28Nov 2Nov 5
Key dataNov 5, 2026
Open$258.00
From 52W high−6.55%
Volume11.78M
Market cap$96.40B
P/E (TTM)—
P/S (TTM)43.3x
Div yield—
Key dataNov 5, 2026
Open
$258.00
From 52W high
−6.55%
Volume
11.78M
Market cap
$96.40B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−32.7x
P/E (TTM)
—
RSI (14)
62.1
MomentumView details →
1D Return
−6.55%
YTD Return
+732.45%
SummaryUpdated Jun 1, 2026
Moderna, Inc. (NASDAQ:MRNA) is a biotechnology company founded in 2010 and headquartered in Cambridge, Massachusetts. The company went public in December 2018 and gained global prominence during the COVID-19 pandemic as one of the first companies to develop and commercialize an mRNA-based vaccine. Originally founded as Moderna Therapeutics, the company changed its name to Moderna, Inc. in August 2018. Today, Moderna has evolved from a single-product COVID vaccine company into a multi-product biotechnology firm with an expanding pipeline of mRNA-based therapeutics and vaccines across multiple disease areas.
Similar companies
Latest newsMore news →
Canada approved Moderna, Inc.'s mRNA influenza vaccine and its combined influenza and COVID-19 vaccine.12h agoModerna, Inc. shares fell sharply, potentially ending a rally driven by optimism about its cancer vaccine.11d agoModerna, Inc. and Merck released detailed results from a late-stage trial showing that adding personalized intismeran to Keytruda reduced the two-year risk of melanoma recurrence by 42% compared with Keytruda alone.12d ago